Table 2.
Pre-infliximab GI toxicity characteristics
| Variable | (N=78) |
| Time to onset of colitis (weeks) | |
| Median (range) | 6 (0, 73) |
| Type of GI toxicity | |
| Colitis | 74 (95%) |
| Upper GI | 3 (4%) |
| Upper and lower GI tract | 1 (1%) |
| Max CTCAE grade | |
| 2 | 4 (5%) |
| 3 | 49 (63%) |
| 4 | 18 (23%) |
| 5 | 6 (7%) |
| Requiring hospitalization | |
| Yes | 62 (79%) |
| Time to commencement of steroids (days) | |
| Median (range) | 2.5 (0, 50) |
| Maximum steroid dose (mg)* | |
| Median (range) | 100 (30, 1250) |
| Type of steroid refractory toxicity | |
| Primary refractory | 46 (59%) |
| Rebound on wean | 32 (41%) |
| Endoscopy pre-infliximab | |
| No | 32 (41%) |
| Sigmoidoscopy (±UGIE) | 24 (31%) |
| Full colonoscopy (±UGIE) | 20 (26%) |
| Upper GI endoscopy (UGIE) only | 2 (3%) |
| Degree of inflammation endoscopically pre-infliximab | |
| Endoscopically normal | 7 (15%) |
| Rectum only | 3 (7%) |
| Sigmoid only | 6 (13%) |
| Left-sided (sigmoid+rectum) | 10 (22%) |
| Pancolitis | 17 (37%) |
| Upper GI tract only | 3 (7%) |
| Time to first dose of infliximab (days) | |
| Median (range) | 17.5 (1, 387) |
*Oral prednisolone equivalent.
CTCAE, Common Terminology Criteria for Adverse Events; GI, gastrointestinal; UGIE, Upper GI endoscopy.